Abbott Norvir Pricing Needs Investigation By FTC, Senators Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Senators Hollings, McCain and Schumer urge FTC to investigate the possible anticompetitive effects that Norvir's price increase may have on other protease inhibitors. The request comes the week before NIH will hold a public meeting to consider granting compulsory licensing of Norvir's patents.
You may also be interested in...
Norvir Federal Grants Were Roughly 1% Of Development Costs, Abbott Says
Abbott's spending on Norvir R&D surpassed $300 mil., Chief Operating Office Jeffrey Leiden, MD/PhD, said
Abbott Norvir Compulsory Licensing Would Take Several Years, NIH Says
NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.
Norvir Federal Grants Were Roughly 1% Of Development Costs, Abbott Says
Abbott's spending on Norvir R&D surpassed $300 mil., Chief Operating Office Jeffrey Leiden, MD/PhD, said